REgenicin

About

Regenicin, Inc. is a biotechnology company dedicated to advancing regenerative cell therapies to repair and restore damaged tissues and organs. Founded in 2010, Regenicin has built a world-class management team with a strong track record in developing and commercializing innovative medical devices and biotechnology products. The company is focused on bringing NovaDerm®—a breakthrough autologous cultured skin substitute—to market. NovaDerm® is a tissue-engineered skin graft that utilizes a patient’s own skin cells to create living, regenerative skin for treating severe burns and chronic wounds. Regenicin is headquartered in Las Vegas, NV.